Page 1, 2, 3
LRA by ELISA/ACT tests are available from:
109 Carpenter Dr., Suite 100
Sterling, Virginia 20164
Nutritional supplements mentioned in this article are available from:
PERQUE Integrative Health
44621 Guilford Drive, Suite 150
Ashburn, Virginia 20147
For functional biomarker tests:
Better Lab Tests Now
Doctor's Data, Inc.
1. Deuster PA, Jaffe R. A novel treatment for fibromyalgia improves clinical outcomes in a community based study. J Musculo Pain, 1998;6:133–149.
2. Jaffe R. First-line comprehensive care III: update on immune system lab tests for fibromyalgia-chronic fatigue-metabolic syndrome: continuum of treatment-resistant pain and fatigue: optimum clinical management improves outcomes and reduces risks and treatment complications as supported by new data. Townsend Lett. 2008;Jan:87–94.
3. Jaffe R, Mani J, DeVane J, Mani H. Tolerance loss in diabetics: association with foreign antigen exposure. Diabet Med. 2006;23(8):924–925.
4. Jaffe R. Quercetin & OPC: nature's solution to inflammation [webinar]. http://bit.ly/10z5ct6.
5. Health Studies Collegium. The Joy of Food: The Alkaline Way Guide. 18th ed. 1992–2010. www.HeatlhStudiesCollegium.org.
6. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology,2012;77(3):212–218.
7. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition (review). Clin Chem Lab Med. 2003 Sep;41(9):1120–1130.
8. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase a2, high-sensitivity c-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842 .
9. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Jul 24;337(4):230–236.
10.Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J.2001 Oct;15(12):2073–2084.
11.Markkanen E, Hübscher U, van Loon B. Regulation of oxidative DNA damage repair: The adenine:8-oxo-guanine problem. Cell Cycle. Epub 2012 Mar 15;11(6).
12.Hohenberger EF, Kimling H. Compendium urinalysis: urinalysis with test strips. 2002 http://www.diavant.com/diavant/servlet/MDBOutput?fileId=1392.
13.Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535–1541.
14.Galen RS, Gambino SR. Beyond Normality: The Predictive Value and Efficiency of Medical Diagnosis. New York: Wiley; 1975.
15.Cheraskin E, Ringsdorf WM Jr, Clark JW. Diet and Disease. Emmaus, PA: Rodale Books; 1968.
16.Williams RJ. Biochemical Individuality: The Key to Understanding What Shapes Your Health. New Canaan, CT: Keats Publishing; 1998.
17.Scadding GK, Brostoff J. Immunological response to food. In: Hunter JO, Jones VA, eds. Food and the Gut. Sussex, UK: Saunders; 1985.
18.Walker WA. Mechanisms of antigen handling by the gut. In: Ballieux I, ed. Clinics in Immunology and Allergy. Sussex, UK: Saunders; 1982.
19.Kotler DP, Gaetz HP, Lange M. Enteropathy associated with the acquired immune deficiency syndrome. Ann Int Med. 1984;101:421–428.
20.Roitt I, Brostoff J, Male D. Immunology. 6th ed. St. Louis: Mosby; 1993.
21.Male D, Brostoff J, Roitt I, Roth DB. Immunology. 7th ed. Mosby Elsevier; 2006.
22.Crisp HC, Quinn JM. Quantitative immunoglobulins in adulthood. Allergy Asthma Proc. 2009;30(6):649–654.
23. Lux A, Aschermann S, Biburger M, Nimmerjahn F. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis. 2010;69 Suppl 1:i92–96.
24. Woof JM, Mestecky J. Mucosal immunoglobulins – review. Immunol Rev. 2005:64–82.
25. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2007;208(2):270–282.
26. Laevy O. Unmasking IgG responses. Nat Rev Immunol. 2006;6:632.
27. Hodsdon, W., Zwickey, H. Reproducibility and reliability of two food allergy testing methods. Nat Med J. 2010;2(3):8–13.
28. Jaffe R. Improved immune function using specific nutrient supplementation and ELISA/ACT "immunologic fingerprint" to detect late phase responses ex vivo. J Am Coll Nutr.1989;8(5):424.
29.Deuster PA, Jaffe R. A novel treatment for fibromyalgia improves clinical outcomes in a community based study. J Musculo Pain. 1998;6:133–149; Jaffe R, Mani J, DeVane J, Mani H. Tolerance loss in diabetics: Association with foreign antigen exposure. Diabet Med. 2006;23(8):924–925.
30.ELISA/ACT Biotechnologies Newsletter. 2010;1(2). Available at www.ELISAACT.com.
31.Jaffe R. Functional lab tests to evaluate immune competencies in chronic illness and chronic infection. Townsend Lett. 2009;306:80–90.
32.Report on Quality Control and Reproducibility of LRA by ELISA/ACT Tests. HSC Report 022010.
33.Hodsdon W, Zwickey H. NMJ original research: reproducibility and reliability of two food allergy testing methods. Nat Med J. 2010;2(3):8–13.
Dr. Russell Jaffe received his AB, MD (with senior thesis honors), and PhD (In biochemistry and physiology) from Boston University. Dr. Jaffe served his medical internship at University Hospital and was awarded a the US Public Health Service Officer Commission, assigned to the Clinical Center of the National Institutes of Health, in June 1973. While at the Clinical Center, Dr. Jaffe served his residency in clinical pathology. He is board certified in clinical and subspecialty certified in chemical pathology. Dr. Jaffe remained on the permanent senior staff of the NIH Clinical Pathology Department, where he continued method innovation and was active in collaborative research with the Laboratory of Experimental Atherosclerosis (of the Heart, Lung, and Blood Institute). Concurrently, Dr. Jaffe's interests in the mechanisms of health and the evoking of human healing responses led him to apprentice in such healing arts as acupuncture; mindfulness; massage; music, art, and color therapy; and a variety of eclectic therapeutic approaches. In addition, Dr. Jaffe performed innovative studies of platelet function and blood clotting in relation to the origins of coronary artery and cardiovascular diseases. Among the tests that he developed are the early colon cancer-screening test using occult blood detection not interfered with by vitamin C consumption, as well as a variety of tests related to the blood clotting and immune defense and repair systems. Dr. Jaffe developed the first method of measuring cell-mediated immunity using a modified ELISA system in a lymphocyte mitogenesis/blastogenesis brief cell culture known as lymphocyte response assays (LRA). This LRA by ELISA/ACT provides an "immunologic fingerprint" of items to which the body is reactive or tolerant. Dr. Jaffe has contributed over 100 symposium-invited talks, scientific articles, or book chapters. He received the J. D. Lane award for original research from the USPHS, the Merck Sharp and Dohme Excellence in Research Award, and in 2002 the International Research Scientist of the Year, among other recognitions for his investigations. Dr. Jaffe is a fellow of the Health Studies Collegium and director of ELISA/ACT Biotechnologies LLC and PERQUE LLC in Ashburn, Virginia. He may be reached at 800-525-7372 ext. 5101, and rjaffe@ELISAACT.com or rjaffe@PERQUE.com.
Jayashree Mani, MS, CCN is a clinical nutritionist with over 20 years' experience in providing nutritional counseling and education to patients and physicians in various medical environments. Her focus over the past 10 years has been on the functional use of lymphocyte cell response assays in clinical management of various autoimmune conditions, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Developing nutritional protocols involving the Alkaline Way and specific nutritional supplementation, her work also includes specific emphasis on diabetes and metabolic syndrome and its management. She has coauthored chapters on these topics and published scientific articles describing these comprehensive approaches as well. She may be contacted at PERQUE Integrative Health/ELISA/ACT Biotechnologies; 800-525-7372 or 703-840-4427; jmani@PERQUE.com or firstname.lastname@example.org.
Page 1, 2, 3